Biological therapies in Crohn’s disease: are they cost-effective? A critical appraisal of model-based analyses

References

• Hutfless S, Lau BD, Wilson LM, et al. Pharmacological management of crohn’s disease: future research needs: identification of future research needs from comparative effectiveness review no. 131. Agency for Healthcare Research and Quality US. 2014; Report No.: 13(14)-EHC017-EF
   Google Scholar
• Terdiman JP, Gruss CB, Heidelbaugh JJ, AGA Institute Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology 2013;145(6):1459-63
   PubMed Web of Science ®Google Scholar
• Orlando A, Armuzzi A, Papi C, et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2011;43(1):1-20
   PubMedGoogle Scholar
• Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Chrohn’s Colitis 2010;4(1):28-62
   PubMed Web of Science ®Google Scholar
• Kawalec P, Mikrut A, Wiśniewska N, Pilc A. Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn’s disease: systematic review and meta-analysis. Arch Med Sci 2013;9(5):765-79
   PubMed Web of Science ®Google Scholar
• Dassopoulos T, Sultan S, Falck-Ytter YT, et al. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology 2013;145(6):1464-78
   PubMed Web of Science ®Google Scholar
• Zhang D, Xiong B, Li X, et al. Meta-analysis: serious adverse events in Crohn’s disease patients treated with TNF-alpha inhibitors. Hepatogastroenterology 2013;60(126):1333-42
   PubMedGoogle Scholar
• Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 2013;108(8):1268-76
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R, et al. Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005;353(18):1912-25
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007;357(3):228-38
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013;369(8):711-21
   PubMed Web of Science ®Google Scholar
• Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn’s disease in the United States and other Western countries: a systematic review. Curr Med Res Opin 2008;24(2):319-28
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Liberato L, Marchetti M, et al. Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. Intern Emerg Med 2011;6(suppl 1):S17-27
   PubMedGoogle Scholar
• Odes S, Vardi H, Friger M, et al. Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn’s disease patients by Markov analysis. Aliment Pharmacol Ther 2010;31(7):735-44
   PubMed Web of Science ®Google Scholar
• Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α)inhibitors, adalimumab and infliximab for Crohn’s disease. Health Technol Assess 2011;15(6):1-250
   PubMed Web of Science ®Google Scholar
• Tang DH, Harrington AR, Lee JK, et al. A systematic review of economic studies on biological agents used to treat Crohn’s disease. Inflamm Bowel Dis 2013;19(12):2673-94
   PubMed Web of Science ®Google Scholar
• de Pouvourville G1, Ulmann P, Nixon J, et al. The diffusion of health economics knowledge in Europe : The EURONHEED (European Network of Health Economics Evaluation Database) project. Pharmacoeconomics 2005;23(2):113-20
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. CHEERS Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care 2013;29(2):117-22
   PubMed Web of Science ®Google Scholar
• Gaultney JG, Redekop WK, Sonneveld P, Uyl-de Groot CA. Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology. Eur J Cancer 2011;47(10):1458-67
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Hur C, Juillerat P, Korzenik JR. Strategies for the prevention of postoperative recurrences in Crohn’s disease: results of a decision analysis. Am J Gastroenterol 2011;106(11):2009-17
   PubMed Web of Science ®Google Scholar
• Punekar YS, Sunderland T, Hawkins N, Lindsay J. Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn’s disease. Value Health 2010;13(2):188-95
   PubMed Web of Science ®Google Scholar
• Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease – modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther 2008;28(1):76-87
   PubMed Web of Science ®Google Scholar
• Arsenau KO, Cohn SM, Cominelli F, Connors AF. Cost-utility of initial medical management of Crohn’s disease perianal fistulae. Gastroenterology 2001;120(7):1640-56
   PubMed Web of Science ®Google Scholar
• Jaisson-Hot I, Flouriè B, Descos L, Colin C. Management for severe Crohn’s disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care 2004;20(3):274-9
   PubMed Web of Science ®Google Scholar
• Marchetti M, Liberato NL, Di Sabatino A, Corazza GR. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn’s disease. Eur J Health Econ 2013;14(6):853-61
   PubMed Web of Science ®Google Scholar
• Marshall J, Blackhouse G, Goeree R, et al. Infliximab for the treatment of Crohn’s disease: a systematic review and cost-utility analysis. Technology report n. 24. Canadian Coordinating Office for Health Technology Assessment, Ottawa; 2002. Available from: www.cadth.ca/media/pdf/122_infliximab_tr_e.pdf [Last accessed 21 June 2014]
   Google Scholar
• Ananthakrishnan AN, Hur C, Korzenik JR. Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn’s disease: results of a decision analysis. Di Dis Sci 2012;57(2):472-80
   PubMed Web of Science ®Google Scholar
• Tang DH, Armstrong EP, Lee JK. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn’ disease. Pharmacotherapy 2012;32(6):515-26
   PubMed Web of Science ®Google Scholar
• Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007;26(11-12):1509-20
   PubMed Web of Science ®Google Scholar
• Blackhouse G, Assasi N, Xie F, et al. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn’s disease. J Crohn’s Colitis 2012;6(1):77-85
   Google Scholar
• Saito S, Shimizu U, Nan Z, et al. A health economic analysis of combination therapy with infliximab plus elemental diet for moderately to severely active Crohn’s disease. Health 2014.6(1):107-14. Available from: http://dx.doi.org/10.4236/health.2014.61017 [Last accessed 21 June 2014]
   Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541-9
   PubMed Web of Science ®Google Scholar
• Sands BE, Blank MA, Patel K, van Deventer SJ; ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004;2(10):912-20
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006;130(2):323-33
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007;56(9):1232-39
   Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146(12):829-38
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE trial. Gastroenterology 2007;132(5):1672-83
   PubMed Web of Science ®Google Scholar
• D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008;371(9613):660-7
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362(15):1383-95
   PubMed Web of Science ®Google Scholar
• Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology 1999;117(1):49-57
   PubMed Web of Science ®Google Scholar
• Gregor JC, McDonald JW, Klar N, et al. An evaluation of utility measurement in Crohn’s disease. Inflamm Bowel Dis 1997;3(4):265-76
   PubMed Web of Science ®Google Scholar
• Casellas S, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005;11(5):488-96
   PubMed Web of Science ®Google Scholar
• Saito S, Shimizu U, Nan Z, et al. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn’s disease: a cost-effectiveness analysis. J Crohn’s Colitis 2013;7(2):167-74
   Google Scholar
• Malone DC, Waters HC, Van Den Bos J, et al. A claims-based Markov model for Crohn’s disease. Aliment Pharmacol Ther 2010;32(3):550-5
   Web of Science ®Google Scholar
• Yu AP, Johnson S, Wang AT, et al. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s disease. Pharmacoeconomics 2009;27(7):609-21
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr, Johnson SJ, Yu AP, et al. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn’s disease. Eur J Gastroenterol 2009;21(11):1302-9
   PubMed Web of Science ®Google Scholar
• Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 2009;30(3):265-74
   PubMed Web of Science ®Google Scholar
• Waljee AK, Morris AM, Waljee JF, et al. Individual health discount rate in patients with ulcerative colitis. Inflamm Bowel Dis 2011;17(6):1328-32
   PubMed Web of Science ®Google Scholar
• Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn’s disease in the United States and other Western countries: a systematic review. Curr Med Res Opin 2008;24(2):319-28
   PubMed Web of Science ®Google Scholar
• Binion DG, Louis E, Oldenburg E, et al. Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn’s disease: a meta-analysis. Can J Gastroenterol 2011;25(9):492-6
   PubMedGoogle Scholar
• Casellas F, Barreiro de Acosta M, Iglesias M, et al. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2012;24(7):762-9
   PubMed Web of Science ®Google Scholar
• Geboes K, Rutgeerts P, Opdenakker G, et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn’s disease. Curr Med Res Opin 2005;21(11):1741-54
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 2010;138(2):463-8
   PubMed Web of Science ®Google Scholar
• Bouguen G, Levesque BG, Feagan BG, et al. Treat to target: a proposed new paradigm for the management of Crohn’s disease. Clin Gastroenterol Hepatol 2013; doi; 10.1016/j.cgh.2013.09.006. [Epub ahead of print]
   Web of Science ®Google Scholar
• Bouguen G, Levesque BG, Pola S, et al. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2014;12(6):978-85
   PubMed Web of Science ®Google Scholar
• Nord E, Johansen R. Concerns for severity in priority setting in health care: a review of trade-off data in preference studies and implications for societal willingness to pay for a QALY. Health Policy 2014;116(2-3):281-8
   PubMed Web of Science ®Google Scholar
• Clark W, Raftery J, Song F, et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn’s disease. Health Technol Assess 2003;7(3):1-77
   PubMedGoogle Scholar